Global Insulin Glargine Injection Market Research Report 2023

Publication ID:

PB503240579

Publication Date:

March 7, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Insulin Glargine Injection market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Insulin Glargine Injection is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Insulin Glargine Injection is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Insulin Glargine Injection include Sanofi, Lilly, Gan & Lee, Tonghua Dongbao Pharmaceutical, HEC Pharm and Boao Bio Harmaceutical, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Insulin Glargine Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Insulin Glargine Injection.
The Insulin Glargine Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Insulin Glargine Injection market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Insulin Glargine Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Sanofi
Lilly
Gan & Lee
Tonghua Dongbao Pharmaceutical
HEC Pharm
Boao Bio Harmaceutical
Segment by Type
Pre-filled
Ordinary
Segment by Application
Hospital
Clinic
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Insulin Glargine Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Insulin Glargine Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Insulin Glargine Injection Market Overview
1.1 Product Overview and Scope of Insulin Glargine Injection
1.2 Insulin Glargine Injection Segment by Type
1.2.1 Global Insulin Glargine Injection Market Value Comparison by Type (2023-2029)
1.2.2 Pre-filled
1.2.3 Ordinary
1.3 Insulin Glargine Injection Segment by Application
1.3.1 Global Insulin Glargine Injection Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Insulin Glargine Injection Market Size Estimates and Forecasts
1.4.1 Global Insulin Glargine Injection Revenue 2018-2029
1.4.2 Global Insulin Glargine Injection Sales 2018-2029
1.4.3 Global Insulin Glargine Injection Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Insulin Glargine Injection Market Competition by Manufacturers
2.1 Global Insulin Glargine Injection Sales Market Share by Manufacturers (2018-2023)
2.2 Global Insulin Glargine Injection Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Insulin Glargine Injection Average Price by Manufacturers (2018-2023)
2.4 Global Insulin Glargine Injection Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Insulin Glargine Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Insulin Glargine Injection, Product Type & Application
2.7 Insulin Glargine Injection Market Competitive Situation and Trends
2.7.1 Insulin Glargine Injection Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Insulin Glargine Injection Players Market Share by Revenue
2.7.3 Global Insulin Glargine Injection Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Insulin Glargine Injection Retrospective Market Scenario by Region
3.1 Global Insulin Glargine Injection Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Insulin Glargine Injection Global Insulin Glargine Injection Sales by Region: 2018-2029
3.2.1 Global Insulin Glargine Injection Sales by Region: 2018-2023
3.2.2 Global Insulin Glargine Injection Sales by Region: 2024-2029
3.3 Global Insulin Glargine Injection Global Insulin Glargine Injection Revenue by Region: 2018-2029
3.3.1 Global Insulin Glargine Injection Revenue by Region: 2018-2023
3.3.2 Global Insulin Glargine Injection Revenue by Region: 2024-2029
3.4 North America Insulin Glargine Injection Market Facts & Figures by Country
3.4.1 North America Insulin Glargine Injection Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Insulin Glargine Injection Sales by Country (2018-2029)
3.4.3 North America Insulin Glargine Injection Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Insulin Glargine Injection Market Facts & Figures by Country
3.5.1 Europe Insulin Glargine Injection Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Insulin Glargine Injection Sales by Country (2018-2029)
3.5.3 Europe Insulin Glargine Injection Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Insulin Glargine Injection Market Facts & Figures by Country
3.6.1 Asia Pacific Insulin Glargine Injection Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Insulin Glargine Injection Sales by Country (2018-2029)
3.6.3 Asia Pacific Insulin Glargine Injection Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Insulin Glargine Injection Market Facts & Figures by Country
3.7.1 Latin America Insulin Glargine Injection Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Insulin Glargine Injection Sales by Country (2018-2029)
3.7.3 Latin America Insulin Glargine Injection Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Insulin Glargine Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa Insulin Glargine Injection Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Insulin Glargine Injection Sales by Country (2018-2029)
3.8.3 Middle East and Africa Insulin Glargine Injection Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Insulin Glargine Injection Sales by Type (2018-2029)
4.1.1 Global Insulin Glargine Injection Sales by Type (2018-2023)
4.1.2 Global Insulin Glargine Injection Sales by Type (2024-2029)
4.1.3 Global Insulin Glargine Injection Sales Market Share by Type (2018-2029)
4.2 Global Insulin Glargine Injection Revenue by Type (2018-2029)
4.2.1 Global Insulin Glargine Injection Revenue by Type (2018-2023)
4.2.2 Global Insulin Glargine Injection Revenue by Type (2024-2029)
4.2.3 Global Insulin Glargine Injection Revenue Market Share by Type (2018-2029)
4.3 Global Insulin Glargine Injection Price by Type (2018-2029)
5 Segment by Application
5.1 Global Insulin Glargine Injection Sales by Application (2018-2029)
5.1.1 Global Insulin Glargine Injection Sales by Application (2018-2023)
5.1.2 Global Insulin Glargine Injection Sales by Application (2024-2029)
5.1.3 Global Insulin Glargine Injection Sales Market Share by Application (2018-2029)
5.2 Global Insulin Glargine Injection Revenue by Application (2018-2029)
5.2.1 Global Insulin Glargine Injection Revenue by Application (2018-2023)
5.2.2 Global Insulin Glargine Injection Revenue by Application (2024-2029)
5.2.3 Global Insulin Glargine Injection Revenue Market Share by Application (2018-2029)
5.3 Global Insulin Glargine Injection Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Corporation Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Insulin Glargine Injection Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Sanofi Insulin Glargine Injection Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 Lilly
6.2.1 Lilly Corporation Information
6.2.2 Lilly Description and Business Overview
6.2.3 Lilly Insulin Glargine Injection Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Lilly Insulin Glargine Injection Product Portfolio
6.2.5 Lilly Recent Developments/Updates
6.3 Gan & Lee
6.3.1 Gan & Lee Corporation Information
6.3.2 Gan & Lee Description and Business Overview
6.3.3 Gan & Lee Insulin Glargine Injection Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Gan & Lee Insulin Glargine Injection Product Portfolio
6.3.5 Gan & Lee Recent Developments/Updates
6.4 Tonghua Dongbao Pharmaceutical
6.4.1 Tonghua Dongbao Pharmaceutical Corporation Information
6.4.2 Tonghua Dongbao Pharmaceutical Description and Business Overview
6.4.3 Tonghua Dongbao Pharmaceutical Insulin Glargine Injection Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Tonghua Dongbao Pharmaceutical Insulin Glargine Injection Product Portfolio
6.4.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates
6.5 HEC Pharm
6.5.1 HEC Pharm Corporation Information
6.5.2 HEC Pharm Description and Business Overview
6.5.3 HEC Pharm Insulin Glargine Injection Sales, Revenue and Gross Margin (2018-2023)
6.5.4 HEC Pharm Insulin Glargine Injection Product Portfolio
6.5.5 HEC Pharm Recent Developments/Updates
6.6 Boao Bio Harmaceutical
6.6.1 Boao Bio Harmaceutical Corporation Information
6.6.2 Boao Bio Harmaceutical Description and Business Overview
6.6.3 Boao Bio Harmaceutical Insulin Glargine Injection Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Boao Bio Harmaceutical Insulin Glargine Injection Product Portfolio
6.6.5 Boao Bio Harmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Insulin Glargine Injection Industry Chain Analysis
7.2 Insulin Glargine Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Insulin Glargine Injection Production Mode & Process
7.4 Insulin Glargine Injection Sales and Marketing
7.4.1 Insulin Glargine Injection Sales Channels
7.4.2 Insulin Glargine Injection Distributors
7.5 Insulin Glargine Injection Customers
8 Insulin Glargine Injection Market Dynamics
8.1 Insulin Glargine Injection Industry Trends
8.2 Insulin Glargine Injection Market Drivers
8.3 Insulin Glargine Injection Market Challenges
8.4 Insulin Glargine Injection Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Sanofi
Lilly
Gan & Lee
Tonghua Dongbao Pharmaceutical
HEC Pharm
Boao Bio Harmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂